No conflict of interest was declared.
Usage of the claim database of national health insurance programme for analysis of cisapride-erythromycin co-medication in Taiwan†
Article first published online: 28 SEP 2006
Copyright © 2006 John Wiley & Sons, Ltd.
Pharmacoepidemiology and Drug Safety
Volume 16, Issue 1, pages 86–95, January 2007
How to Cite
Gau, C.-S., Chang, I.-S., Lin Wu, F.-L., Yu, H.-T., Huang, Y.-W., Chi, C.-L., Chien, S.-Y., Lin, K.-M., Liu, M.-Y. and Wang, H.-P. (2007), Usage of the claim database of national health insurance programme for analysis of cisapride-erythromycin co-medication in Taiwan. Pharmacoepidem. Drug Safe., 16: 86–95. doi: 10.1002/pds.1324
- Issue published online: 20 DEC 2006
- Article first published online: 28 SEP 2006
- Manuscript Accepted: 13 AUG 2006
- Manuscript Revised: 7 APR 2006
- Manuscript Received: 29 SEP 2005
- claim data;
- National Health Insurance Research Database
This study aimed to use the National Health Insurance Research Database, Taiwan for risk analysis of concomitant use of cisapride and erythromycin.
The sample consisted of subjects identified in the Outpatient Sampling Database (OSD) and Longitudinal Health Insurance Database 2000 (LHID 2000), derived from the original claim data of the National Health Insurance Research Database, Taiwan.
According to the LHID 2000, a total of 464 individuals experienced 685 episodes of cisapride-erythromycin co-medication prescribed by 295 physicians, revealing a prevalence of 4.5% concomitant use, with higher prevalence in clinics (9.2%) than in other medical institutes (3.7–5.4%). Among the co-medication episodes, 81.9% and 61.2% were prescribed from the same health institutes and by the same physicians, respectively. No medical record of cardiac arrhythmias was found among these patients in 2001 and 2002, probably due to the fact that 78.9% of the 464 individuals were under age 16, 84.0% had short exposure duration (1–4 days) and 98.0% of the episodes were prescribed with a cisapride dose of less than 0.8 mg/kg/day.
Findings from this study suggest that there exists an urgent need for accreditation in terms of pharmacovigilance of clinical sites and their practicing physicians for the prevention of irrational concomitant prescription in Taiwan. Our findings also indicate that it is necessary to investigate other possible conditions of potentially dangerous co-medication in Taiwan and other developing countries. Copyright © 2006 John Wiley & Sons, Ltd.